Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Perspective Therapeutics (CATX) Gross Margin (2016 - 2023)

Perspective Therapeutics (CATX) has disclosed Gross Margin for 14 consecutive years, with 1.02% as the latest value for Q4 2023.

  • Quarterly Gross Margin changed N/A to 1.02% in Q4 2023 from the year-ago period, while the trailing twelve-month figure was 56.66% through Dec 2023, up 1766.0% year-over-year, with the annual reading at 100.0% for FY2023, N/A changed from the prior year.
  • Gross Margin hit 1.02% in Q4 2023 for Perspective Therapeutics, down from 33.78% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 59.24% in Q1 2020 to a low of 1.02% in Q4 2023.
  • Historically, Gross Margin has averaged 40.5% across 5 years, with a median of 45.69% in 2019.
  • Biggest five-year swings in Gross Margin: skyrocketed 1984bps in 2019 and later crashed -2591bps in 2023.
  • Year by year, Gross Margin stood at 50.36% in 2019, then decreased by -2bps to 49.47% in 2020, then fell by -12bps to 43.32% in 2021, then crashed by -44bps to 24.11% in 2022, then tumbled by -96bps to 1.02% in 2023.
  • Business Quant data shows Gross Margin for CATX at 1.02% in Q4 2023, 33.78% in Q3 2023, and 11.88% in Q2 2023.